

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS 18 JAN 12 Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19 JAN 25 Annual Reload of MEDLINE database
NEWS 20 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 24 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:25:44 ON 29 MAR 2010

FILE 'REGISTRY' ENTERED AT 10:26:11 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8
DICTIONARY FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8

New CAS Information Use Policies. enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10595891latest.str




```
chain nodes :
11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
3-13 9-11 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
3-13 5-7 6-10 7-8 8-9 9-10 9-11 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :
```

G1:N,CH

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
```

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.


```
=> s l1 sss full
FULL SEARCH INITIATED 10:26:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 79487 TO ITERATE
```

```
100.0% PROCESSED 79487 ITERATIONS 291 ANSWERS
SEARCH TIME: 00.00.01
```

L2 291 SEA SSS FUL L1

=> d scan



```
L2 291 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2,3-Quinoxalinedione, 6-(3-fluorobenzoyl)-1,4-dihydro-
MF C15 H9 F N2 O3
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=>
Uploading C:\Program Files\STNEXP\Queries\10595891last.str
```




```
chain nodes :
11 13 14 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
3-13 8-24 9-11 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
3-13 5-7 8-24 13-14 14-15
exact bonds :
6-10 7-8 8-9 9-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :
```

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
24:CLASS

L3 STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

```
=> s 13
SAMPLE SEARCH INITIATED 10:28:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 319 TO ITERATE

100.0% PROCESSED      319 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS:      5309 TO      7451
PROJECTED ANSWERS:          0 TO          0
```

L4 0 SEA SSS SAM L3

```
=> s 13 sss full
FULL SEARCH INITIATED 10:28:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6242 TO ITERATE

100.0% PROCESSED      6242 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.02
```

L5 0 SEA SSS FUL L3

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	385.04	385.26

```
FILE 'CAPLUS' ENTERED AT 10:29:32 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 29 Mar 2010 VOL 152 ISS 14

FILE LAST UPDATED: 28 Mar 2010 (20100328/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12
L6 18 L2

=> s 12 and (pry<2004 or py<2004)
18 L2
4301790 PRY<2004
24050550 PY<2004
L7 15 L2 AND (PRY<2004 OR PY<2004)

=> d 1-15 ibib abs hitstr

L7 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:523430 CAPLUS
DOCUMENT NUMBER: 143:60003
TITLE: Preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-Pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054210	A1	20050616	WO 2004-EP13164	20041118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295059	A1	20050616	AU 2004-295059	20041118 <--
CA 2546657	A1	20050616	CA 2004-2546657	20041118 <--

EP 1709012	A1	20061011	EP 2004-819602	20041118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				
HR, IS, YU				
CN 1890224	A	20070103	CN 2004-80035857	20041118 <--
BR 2004016532	A	20070109	BR 2004-16532	20041118 <--
JP 2007513101	T	20070524	JP 2006-541830	20041118 <--
SG 151249	A1	20090430	SG 2009-1531	20041118 <--
IN 2006DN03071	A	20070810	IN 2006-DN3071	20060529 <--
US 20070129375	A1	20070607	US 2006-596086	20060530 <--
MX 2006006255	A	20060809	MX 2006-6255	20060602 <--
KR 2006118534	A	20061123	KR 2006-711234	20060608 <--
NO 2006003028	A	20060628	NO 2006-3028	20060628 <--
PRIORITY APPLN. INFO.:			EP 2003-78859	A 20031205 <--
			WO 2004-EP13164	W 20041118

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:60003; MARPAT 143:60003

GI



AB The title compds. I [$n = 0-2$; X = N, CR5; R5 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thienyl; R2 = H, OH, or taken together with R3 or R4 may form O; R3 = OH, OR8, SR9, etc.; R8 = alkyl, alkylcarbonyl, dialkylaminoalkyl; R9 = dialkylaminoalkyl; R4 = H, alkyl, furanyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared. E.g., a multi-step synthesis of II, starting from 1-(4-amino-3-nitrophenyl)-2-methyl-1-propanone, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 854523-82-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854523-82-3 CAPLUS

CN Formamide, N-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-phenylpropyl]-
(CA INDEX NAME)



IT 854524-08-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as
 poly(ADP-ribose) polymerase inhibitors)
 RN 854524-08-6 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:523424 CAPLUS
 DOCUMENT NUMBER: 143:60001
 TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted
 2-quinolinones and 2-quinoxalinones as
 poly(ADP-ribose) polymerase inhibitors
 INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome
 Emile Georges; Van Dun, Jacobus Alphonsus Josephus;
 Somers, Maria Victorina Francisca; Wouters, Walter
 Boudewijn Leopold
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054201	A1	20050616	WO 2004-EP13163	20041118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295058	A1	20050616	AU 2004-295058	20041118 <--
CA 2546300	A1	20050616	CA 2004-2546300	20041118 <--
EP 1687277	A1	20060809	EP 2004-819601	20041118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1882547	A	20061220	CN 2004-80034176	20041118 <--

BR 2004016206	A	20061226	BR 2004-16206	20041118 <--
JP 2007511574	T	20070510	JP 2006-540338	20041118 <--
SG 150533	A1	20090330	SG 2009-1197	20041118 <--
NZ 546991	A	20100129	NZ 2004-546991	20041118 <--
US 20070072842	A1	20070329	US 2006-595891	20060518 <--
IN 2006DN02813	A	20070803	IN 2006-DN2813	20060518 <--
MX 2006005687	A	20060817	MX 2006-5687	20060519 <--
ZA 2006004075	A	20070926	ZA 2006-4075	20060519 <--
KR 2006115393	A	20061108	KR 2006-710201	20060525 <--
NO 2006002894	A	20060809	NO 2006-2894	20060620 <--
PRIORITY APPLN. INFO.:			WO 2003-EP13028	A 20031120 <--
			EP 2003-78860	A 20031205 <--
			WO 2003-EP130	A 20031120 <--
			WO 2004-EP13163	W 20041118

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:60001; MARPAT 143:60001

GI




AB The title compds. I [n = 0-2; X = N, CR7; R7 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thiophenyl; R2 = H, OH, alkyl, alkynyl or taken together with R3 may form O; R3 = OH, OR10, SR11, etc.; R10, R11 = CHO, alkyl, (alkyl)amino, etc.; R4-R6 = H, halo, trihalomethyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from bromobenzene and 3-methyl-6-quinolinecarboxaldehyde, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 854532-59-5P 854532-61-9P 854533-52-1P
 854533-95-2P 854534-00-2P 854534-03-5P
 854534-17-1P 854534-18-2P 854534-19-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854532-59-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]-3-ethyl-
(CA INDEX NAME)




RN 854532-61-9 CAPLUS
CN 6-Quinolineacetonitrile, 1,2-dihydro-3-methyl-2-oxo- α -phenyl- (CA INDEX NAME)




RN 854533-52-1 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-95-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinoliny)phenylmethyl]- (CA INDEX NAME)




RN 854534-00-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(hydroxyphenylmethyl)- (CA INDEX NAME)



RN 854534-03-5 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-17-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-18-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-19-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylidenemethyl]-3-ethyl- (CA INDEX NAME)




IT	130346-68-8P	130346-69-9P	854532-58-4P
	854532-60-8P	854532-62-0P	854532-63-1P
	854532-64-2P	854532-65-3P	854532-66-4P
	854532-67-5P	854532-69-7P	854532-70-0P
	854532-71-1P	854532-72-2P	854532-73-3P
	854532-74-4P	854532-75-5P	854532-76-6P
	854532-77-7P	854532-78-8P	854532-79-9P
	854532-80-2P	854532-81-3P	854532-82-4P
	854532-83-5P	854532-84-6P	854532-85-7P
	854532-86-8P	854532-87-9P	854532-89-1P
	854532-92-6P	854532-93-7P	854532-94-8P
	854532-95-9P	854532-96-0P	854532-97-1P
	854532-98-2P	854533-00-9P	854533-02-1P
	854533-04-3P	854533-06-5P	854533-07-6P
	854533-09-8P	854533-14-5P	854533-16-7P
	854533-18-9P	854533-20-3P	854533-21-4P
	854533-23-6P	854533-25-8P	854533-27-0P
	854533-29-2P	854533-30-5P	854533-31-6P
	854533-32-7P	854533-33-8P	854533-34-9P
	854533-35-0P	854533-36-1P	854533-37-2P
	854533-38-3P	854533-39-4P	854533-40-7P
	854533-41-8P	854533-42-9P	854533-43-0P
	854533-44-1P	854533-45-2P	854533-46-3P
	854533-47-4P	854533-48-5P	854533-49-6P
	854533-51-0P	854533-53-2P	854533-54-3P
	854533-55-4P	854533-56-5P	854533-57-6P
	854533-58-7P	854533-59-8P	854533-60-1P
	854533-62-3P	854533-65-6P	854533-67-8P
	854533-69-0P	854533-71-4P	854533-73-6P
	854533-75-8P	854533-79-2P	854533-81-6P
	854533-83-8P	854533-85-0P	854533-87-2P
	854533-89-4P	854533-91-8P	854533-93-0P
	854533-97-4P	854533-98-5P	854533-99-6P
	854534-01-3P	854534-02-4P	854534-04-6P
	854534-05-7P	854534-06-8P	854534-07-9P
	854534-08-0P	854534-09-1P	854534-10-4P
	854534-11-5P	854534-12-6P	854534-13-7P
	854534-14-8P	854534-15-9P	854534-16-0P
	854534-20-6P	854534-21-7P	854534-22-8P
	854534-23-9P	854534-24-0P	854534-25-1P
	854534-26-2P	854534-27-3P	854534-28-4P
	854534-29-5P	854534-30-8P	854534-31-9P
	854534-32-0P	854534-33-1P	854535-35-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 130346-68-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl-
(CA INDEX NAME)




RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-58-4 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(methylamino)phenylmethyl]- (CA INDEX NAME)




RN 854532-60-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(acetyloxy)phenylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-62-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 854532-63-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(dimethylamino)phenylmethyl]-3-methyl- (CA INDEX NAME)




RN 854532-64-2 CAPLUS
 CN Urea, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N'-(3-(1-piperidinyl)propyl)- (CA INDEX NAME)




RN 854532-65-3 CAPLUS
 CN Acetamide, N-[2-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-2-phenylethyl]- (CA INDEX NAME)




RN 854532-66-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-(methoxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854532-67-5 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-1H-imidazol-5-yl)phenylmethyl]-
(CA INDEX NAME)



RN 854532-69-7 CAPLUS
CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-ethyl- (CA
INDEX NAME)




RN 854532-70-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-
piperidinyl]phenylmethyl]- (CA INDEX NAME)



RN 854532-71-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-
2-propen-1-yl]-4-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854532-72-2 CAPLUS

CN Piperidinium, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]-1,1-bis[(2E)-3-phenyl-2-propen-1-yl]-, chloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● Cl⁻


RN 854532-73-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)





RN 854532-74-4 CAPLUS

CN 2 (1H)-Quinolinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-75-5 CAPLUS

CN Formamide, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854532-76-6 CAPLUS

CN 2(1H)-Quinoxalininone, 6-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-77-7 CAPLUS


CN 2-(4-chlorophenyl)-6-[(2-ethyl-1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-78-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-79-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-80-2 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[[3-(2-thienyl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-81-3 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[3-(1H-pyrrol-1-yl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-82-4 CAPLUS
CN Acetamide, N-[2-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]amino]ethyl]- (CA INDEX NAME)




RN 854532-83-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[phenyl[3-(1-piperidinyl)propyl]amino]methyl]- (CA INDEX NAME)



RN 854532-84-6 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(3-oxo-3-phenylpropyl)amino]phenylmethyl]- (CA INDEX NAME)




RN 854532-85-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2-(dimethylamino)ethoxy)phenylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-86-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2-hydroxyethyl)amino]phenylmethyl]-3-methyl- (CA INDEX NAME)



RN 854532-87-9 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 854532-89-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperidinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854532-88-0


CMF C32 H41 N3 O3



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 854532-92-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)

MeO—CH₂—CH₂—NH




RN 854532-93-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 854532-94-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[2-fluoro-4-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854532-95-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-[3-(dimethylamino)propoxy]phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854532-96-0 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854532-97-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl-
(CA INDEX NAME)



RN 854532-98-2 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)phenylmethyl]-
(CA INDEX NAME)




RN 854533-00-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (1:3)
(CA INDEX NAME)

CM 1

CRN 854532-99-3


CMF C31 H40 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-02-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-(cyclohexylmethyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-01-0


CMF C31 H39 N3 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 854533-04-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[6-fluoro-3-(4-piperidinyl)-1H-indazol-1-yl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-06-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-05-4


CMF C32 H42 N4 O3




CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 854533-07-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-09-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-14-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]phenylmethyl]-, ethanedioate (2:5) (CA INDEX NAME)


CM 1

CRN 854533-13-4
CMF C31 H33 F N4 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-16-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[phenyl[[3-(1-piperidinyl)propyl]amino]methyl]-, ethanedioate (2:5) (CA INDEX NAME)


CM 1

CRN 854533-15-6
CMF C25 H32 N4 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-18-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-(1-piperidinyl)propyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-17-8
CMF C28 H35 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 854533-20-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[1-(phenylmethyl)-3-piperidinyl]amino]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)


CM 1

CRN 854533-19-0
CMF C32 H35 N3 O3




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 854533-21-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-23-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-22-5


CMF C24 H28 N2 O4



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-25-8 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-24-7
CMF C28 H32 N4 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-27-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[(3-[methyl(phenylmethyl)amino]propyl)amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-26-9
CMF C31 H35 N3 O3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-29-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-methoxyethyl)amino]phenylmethyl-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-28-1
CMF C21 H24 N2 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 854533-30-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-31-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-32-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[4-[(2-methoxyethyl)amino]-1-piperidinyl]-2-naphthalenylmethyl- (CA INDEX NAME)




RN 854533-33-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl- (CA INDEX NAME)




RN 854533-34-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chloro-3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-35-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,4-dimethylphenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-36-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-(dimethylamino)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-37-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-38-3 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-39-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,4-difluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-40-7 CAPLUS
 CN 2(1H)-Quinolinone, 6-[[2-chloro-5-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-41-8 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[4-[(2-methoxyethyl)amino]-1-piperidinyl]-[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854533-42-9 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-43-0 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[4H-1,2,4-triazol-4-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)





RN 854533-44-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,6-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-45-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-46-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-1-naphthalenylmethyl]- (CA INDEX NAME)




RN 854533-48-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-49-6 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-51-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[[2-(dimethylamino)ethoxy][3-(trifluoromethyl)phenyl]methyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 854533-50-9

CMF C₂₃ H₂₅ F₃ N₂ O₂





CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854533-53-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[4-[(2-methoxyethyl)amino]-1-piperidinyl](2-methylphenyl)methyl]- (CA INDEX NAME)




RN 854533-54-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA INDEX NAME)




RN 854533-56-5 CAPLUS
CN 6-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -phenyl- (CA INDEX NAME)




RN 854533-57-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-58-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-[(2-methoxyethyl)amino]-1-piperidinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-59-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-60-1 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[1-phenyl-3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 854533-62-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)propyl]-3-ethyl- (CA INDEX NAME)



RN 854533-65-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]propyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 854533-64-5
CMF C23 H25 F3 N2 O




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854533-67-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-phenylpropyl]-3-ethyl- (CA INDEX NAME)




RN 854533-69-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1-piperidinylmethyl)- (CA INDEX NAME)




RN 854533-71-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-73-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-75-8 CAPLUS
 CN Formamide, N-[(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)




RN 854533-79-2 CAPLUS
 CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl) (3-methylphenyl)methyl]- (CA INDEX NAME)




RN 854533-81-6 CAPLUS
 CN Formamide, N-[1,3-benzodioxol-5-yl(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-83-8 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(formylamino)methyl]-, ethyl ester (CA INDEX NAME)




RN 854533-85-0 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl) (3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 854533-87-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl) (4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 854533-89-4 CAPLUS
CN Formamide, N-[3-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-1-phenylpropyl]- (CA INDEX NAME)




RN 854533-91-8 CAPLUS
CN Formamide, N-[(3-chlorophenyl) (1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-93-0 CAPLUS
CN Formamide, N-[(4-chlorophenyl) (1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-97-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[hydroxy(3-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 854533-98-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)



RN 854533-99-6 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)hydroxymethyl]-, ethyl ester (CA INDEX NAME)




RN 854534-01-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-methyl- (CA INDEX NAME)




RN 854534-02-4 CAPLUS

CN 2(1H)-Quinolinone, 6-(1-hydroxy-1-phenyl-2-propyn-1-yl)-3-methyl- (CA INDEX NAME)




RN 854534-04-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-05-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854534-06-8 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-oxo-2-phenylethyl)- (CA INDEX NAME)




RN 854534-07-9 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-cyclohexyl-1-piperazinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-08-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[3-(4-chlorophenyl)-3-(1H-imidazol-1-yl)propyl]-3-ethyl- (CA INDEX NAME)




RN 854534-09-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)



RN 854534-10-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[1-(4-chlorophenyl)-2-(3-ethyl-1,2-dihydro-2-oxo-6-quinoxalinyl)ethyl]- (CA INDEX NAME)




RN 854534-11-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-12-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl) (4-methyl-1H-imidazol-1-yl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-13-7 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-14-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-15-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-
(CA INDEX NAME)




RN 854534-16-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl-
(CA INDEX NAME)




RN 854534-20-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-21-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-22-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinylidene)phenylmethyl]- (CA INDEX NAME)




RN 854534-23-9 CAPLUS
CN 2(1H)-Quinolinone, 5-[(1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-(dimethylamino)-1-propen-1-yl)-3-methyl- (CA INDEX NAME)



RN 854534-24-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-25-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(4-chlorophenyl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-26-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-27-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1E)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-28-4 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1Z)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-29-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-30-8 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-31-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-32-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 854534-33-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 854535-35-6 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



IT 854534-37-5P 854534-38-6P 854534-40-0P

854534-42-2P 854534-48-8P 854534-49-9P


854534-50-2P 854534-51-3P 854534-52-4P

854534-53-5P 854534-62-6P 854534-64-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854534-37-5 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-methyl- (CA INDEX NAME)




RN 854534-38-6 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N-methyl- (CA INDEX NAME)




RN 854534-40-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxymethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-42-2 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-ethyl- (CA INDEX NAME)




RN 854534-48-8 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-49-9 CAPLUS


CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl-, hydrochloride (1:1)
(CA INDEX NAME)



● HC1


RN 854534-50-2 CAPLUS

CN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-51-3 CAPLUS

CN 2(1H)-Quinolinone, 6-(2-amino-1-phenylethyl)-3-methyl- (CA INDEX NAME)




RN 854534-52-4 CAPLUS

CN 2(1H)-Quinolinone, 6-(hydroxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-53-5 CAPLUS

CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-62-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-ethyl- (CA INDEX NAME)



RN 854534-64-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[{(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylmethyl}-3-ethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:430796 CAPLUS

DOCUMENT NUMBER: 141:7139

TITLE: Preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis


INVENTOR(S): Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng;
Brittelli, David R.; Burke, Michael J.; Chen, Gang;
Cook, James; Dumas, Jacques; Sibley, Robert; Turner,
Michael R.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043950	A1	20040527	WO 2003-US36003	20031110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505819	A1	20040527	CA 2003-2505819	20031110 <--
AU 2003290744	A1	20040603	AU 2003-290744	20031110 <--
EP 1565455	A1	20050824	EP 2003-783328	20031110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016169	A	20050927	BR 2003-16169	20031110 <--
CN 1738814	A	20060222	CN 2003-80108639	20031110 <--
JP 2006509840	T	20060323	JP 2005-507146	20031110 <--
MX 2005004779	A	20050722	MX 2005-4779	20050504 <--
US 20060004011	A1	20060105	US 2005-534215	20050506 <--
NO 2005002796	A	20050609	NO 2005-2796	20050609 <--
PRIORITY APPLN. INFO.:				
			US 2002-425490P	P 20021112 <--
			US 2003-460915P	P 20030407 <--
			US 2003-484202P	P 20030630 <--
			WO 2003-US36003	W 20031110 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:7139

GI




AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF₃, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy,

amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO₂, NH₂, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thiaryl, pyrrolyl, pyrimidinyl, oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with angiogenesis (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).


IT 694531-84-5P 694531-85-6P 694531-86-7P
 694531-93-6P 694532-04-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiproliferative and angiogenesis inhibitor; preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis)

RN 694531-84-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 694531-85-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[(4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)




RN 694531-86-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-piperidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)




RN 694531-93-6 CAPLUS

CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694532-04-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-amino-2-(7-benzoyl-3,4-dihydro-3-oxo-2-quinoxalinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:796538 CAPLUS

DOCUMENT NUMBER: 139:323440

TITLE: Preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomography.

INVENTOR(S): Lesage, Anne Simone Josephine; Bischoff, Francois Paul; Janssen, Cornelus Gerardus Maria; Lavreysen, Hilde

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2003082350	A2	20031009	WO 2003-EP3240	20030326 <--
WO 2003082350	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479109	A1	20031009	CA 2003-2479109	20030326 <--
AU 2003226737	A1	20031013	AU 2003-226737	20030326 <--
AU 2003226737	B2	20080904		
BR 2003008945	A	20050104	BR 2003-8945	20030326 <--
EP 1492571	A2	20050105	EP 2003-745282	20030326 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642580	A	20050720	CN 2003-807387	20030326 <--
JP 2005524679	T	20050818	JP 2003-579882	20030326 <--
NZ 535438	A	20060831	NZ 2003-535438	20030326 <--
IN 2004DN02631	A	20050401	IN 2004-DN2631	20040908 <--
US 20060083676	A1	20060420	US 2004-509069	20040924 <--
US 7517517	B2	20090414		
MX 2004009435	A	20050125	MX 2004-9435	20040928 <--
ZA 2004007820	A	20051011	ZA 2004-7820	20040928 <--
NO 2004004635	A	20041027	NO 2004-4635	20041027 <--
PRIORITY APPLN. INFO.:			EP 2002-76254	A 20020329 <--
			WO 2003-EP3240	W 20030326 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:323440

GI




AB Radiolabeled title compds. [I, II; X = O, S, C(R6)2, NR7; Y = O, S; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, thienyl, quinolinyl, etc.; R2 = H, halo, cyano, alkyl, amino, heterocyclyl, etc.; R3, R4 = H, halo, OH, cyano, alkyl, alkoxy, etc.; R2R3 = (CH2)3-6, Z4CH2CH2CH2, Z4CH2CH2, etc.; Z4 = O, S, SO2, NR11; R11 = H, alkyl, PhCH2, alkoxycarbonyl; R3R4 = (CH2)4, CH:CHCH:CH; R5 = H, cycloalkyl, piperidinyl, oxothienyl, tetrahydrothienyl, aralkyl, alkoxyalkyl, etc.; R6

= H, aryl, alkyl, aminoalkyl; R7 = amino, OH], were prepared. Most preferred are radiolabeled compds. in which the radioactive isotope is selected from 3H, 11C and 18F. The invention also relates to their use in a diagnostic method, in particular for marking and identifying a mGluR1 receptor in biol. material, as well as to their use for imaging an organ, in particular using positron emission tomog. (PET). Thus, title compound (III) was prepared by tritiation of the corresponding bromide in THF using tritium gas and Pd/C catalyst. The purified product showed specific activity of 25 Ci/mmol.

IT 409344-47-4P 409344-48-5P 409344-56-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomog.)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:275968 CAPLUS



DOCUMENT NUMBER: 136:309857

TITLE: Preparation of quinolines and quinolinones as

INVENTOR(S): metabotropic glutamate receptor antagonists
 Mabire, Dominique Jean-Pierre; Venet, Marc Gaston;
 Coupa, Sophie; Poncelet, Alain Philippe; Lesage, Anne
 Simone Josephine
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028837	A1	20020411	WO 2001-EP11135	20010925 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421782	A1	20020411	CA 2001-2421782	20010925 <--
AU 2001093847	A	20020415	AU 2001-93847	20010925 <--
BR 2001014253	A	20030701	BR 2001-14253	20010925 <--
EP 1332133	A1	20030806	EP 2001-974298	20010925 <--
EP 1332133	B1	20080709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002167	A2	20031028	HU 2003-2167	20010925 <--
JP 2004510764	T	20040408	JP 2002-532423	20010925 <--
NZ 524945	A	20050128	NZ 2001-524945	20010925 <--
EE 200300126	A	20050415	EE 2003-126	20010925 <--
EE 5195	B1	20090817		
CN 1703403	A	20051130	CN 2001-816717	20010925 <--
AU 2001293847	B2	20070524	AU 2001-293847	20010925 <--
AT 400558	T	20080715	AT 2001-974298	20010925 <--
ES 2309095	T3	20081216	ES 2001-974298	20010925 <--
IL 155163	A	20090803	IL 2001-155163	20010925 <--
TW 306854	B	20090301	TW 2001-90124220	20011002 <--
KR 818965	B1	20080404	KR 2003-702014	20030211 <--
HR 2003000229	A2	20030630	HR 2003-229	20030324 <--
IN 2003MN00328	A	20050211	IN 2003-MN328	20030324 <--
BG 107672	A	20040130	BG 2003-107672	20030326 <--
ZA 2003002515	A	20040630	ZA 2003-2515	20030331 <--
NO 2003001474	A	20030505	NO 2003-1474	20030401 <--
NO 325079	B1	20080128		
MX 2003002907	A	20030624	MX 2003-2907	20030401 <--
US 20040082592	A1	20040429	US 2003-381987	20030814 <--
US 7115630	B2	20061003		
US 20050209273	A1	20050922	US 2005-133678	20050520 <--
US 7629468	B2	20091208		
PRIORITY APPLN. INFO.:			EP 2000-203419	A 20001002 <--
			WO 2001-EP11135	W 20010925 <--
			US 2003-381987	A3 20030814 <--

OTHER SOURCE(S): MARPAT 136:309857
 GI




AB The title compds. [I or II; X = O, C(R₆)₂; (wherein R₆ = H, aryl, alkyl, etc.); R₁ = alkyl, aryl, thiienyl, etc.; R₂ = H, halo, CN, etc.; R₃, R₄ = H, alkyl; or R₂ and R₃ may be taken together to form (CH₂)₃, (CH₂)₄, CH:CHCH:CH, etc.; or R₃ and R₄ may be taken together to form CH:CHCH:CH, (CH₂)₄; R₅ = H, cycloalkyl, piperidinyl, etc.; Y = O, S; or Y and R₅ may be taken together to form CH:NN, N:NN, NCH:CH], useful for treating or preventing glutamate-induced diseases of the central nervous system, were prepared Thus, reacting cis-III [R = Cl] with SnMe₄ in the presence of Pg(PPh₃)₄ in PhMe afforded 17% cis-III [R = Me] which showed antagonism at a dose of 2.5 mg/kg bodyweight in cold allodynia test in rats with a Bennett ligation.

IT 409344-47-4P 409344-48-5P 409344-56-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:476381 CAPLUS
DOCUMENT NUMBER: 135:100164
TITLE: (R)-1-{(2-Oxo-1,2-dihydroquinolin-6-yl)[3-(trifluoromethyl)phenyl]methyl}-1H-1,2,4-triazol-4-ium bromide
AUTHOR(S): Peeters, Oswald M.; Blaton, Norbert M.; De Ranter, Camiel J.
CORPORATE SOURCE: Faculteit Farmaceutische Wetenschappen, Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2001), E57(7), o655-o656
CODEN: ACSEBH; ISSN: 1600-5368
URL: <http://journals.iucr.org/e/issues/2001/07/00/ya6033/ya6033.pdf>

PUBLISHER: International Union of Crystallography

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB The metabolism of all-trans-retinoic acid is mediated by a cytochrome dependent P 450 system. The title compound, C₁₉H₁₄F₃N₄O⁺·Br⁻ (R111214), is an inhibitor of P 450. The three planar ring systems, viz. the triazolyl, Ph and quinolinone groups, are arranged in a propeller-like fashion around the central CH group. The dihedral angles formed by the triazolyl/phenyl, triazolyl/quinolinone and phenyl/quinolinone planes are 55.8(1), 79.85(9) and 78.49(9)°, resp. The N-H...O H bonds, involving the triazolium N-H group and the quinolinone O atom, link the cations into infinite chains stretching along the c axis of the crystal. Crystallog. data are given.


IT 349553-99-7

RL: PRP (Properties)
(crystal structure of)

RN 349553-99-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[(R)-1H-1,2,4-triazol-1-yl[4-(trifluoromethyl)phenyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HBr


REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:223060 CAPLUS
 DOCUMENT NUMBER: 135:5590
 TITLE: Some nucleophilic reactions with 6-benzoyl-2,3-dichloroquinoxaline: synthesis of tetrazolo[1,5-a]quinoxoline, 2-methylidene-1,3-dithiolo[4,5-b]quinoxalines, quinoxalino[2,3-b]quinoxalines and pyrazolo[1',5':1,2]imidazolo[4,5-b]-quinoxalines
 AUTHOR(S): El-Gaby, M. S. A.; El-Sharief, A. M. Sh; Ammar, Y. A.; Mohamed, Y. A.; El-Salam, A. A. Abd
 CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Al-Azhar University at Assiut, Assiut, 71524, Egypt
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(3), 195-200
 CODEN: IJSBDB; ISSN: 0376-4699
 PUBLISHER: National Institute of Science Communication, CSIR
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:5590
 AB The starting material 6-benzoyl-2,3-dichloroquinoxaline is subjected to some nucleophilic reagents to study the effect of the benzoyl group on the reactivity of the two chlorine atoms.
 IT 143702-68-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactions of 6-benzoyl-2,3-dichloroquinoxaline with nucleophiles)
 RN 143702-68-5 CAPLUS
 CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:527827 CAPLUS
 DOCUMENT NUMBER: 134:162992
 TITLE: Synthesis and antimicrobial activities of some novel quinoxalinone derivatives
 AUTHOR(S): Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.; Ammar, Y. A.
 CORPORATE SOURCE: Dep. of Chemistry, Faculty of Science, Al-Azhar Univ., Cairo, 11884, Egypt
 SOURCE: Molecules [online computer file] (2000), 5(6), 864-873
 CODEN: MOLEFW; ISSN: 1420-3049
 URL: <http://www.mdpi.org/molecules/papers/50600864.pdf>
 PUBLISHER: Molecular Diversity Preservation International
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:162992
 GI



AB Condensation of 4-benzoyl-1,2-phenylenediamine with sodium pyruvate in acetic acid furnished two products, which were identified as 6-benzoyl- (I) and 7-benzoyl-3-methyl-2(1H)-quinoxalinone (II). Fusion of I with aromatic aldehydes furnished the styryl derivs. Alkylation of I and II with di-Me sulfate or Et chloroacetate produced the N-alkyl derivs. Hydrazinolysis of one ester derivative with hydrazine hydrate afforded the hydrazide derivative, which underwent condensation with aldehydes to give the corresponding hydrazone derivs. In addition, chlorination of I with thionyl chloride afforded the 2-chloro derivative, which was subjected to reaction with sodium azide and n-butylamine to yield the corresponding tetrazolo (III) and n-butylamino (IV) derivs., resp. The structures of the compds. prepared were confirmed by anal. and spectral data. Also, some of the synthesized compds. were screened for antimicrobial activity.


IT 325469-51-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and antimicrobial activities of quinoxalinone derivs.)

RN 325469-51-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-methyl- (CA INDEX NAME)




IT 325469-54-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-54-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-methoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




IT 325469-53-2P 325469-55-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-53-2 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-chlorophenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 325469-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



OS.CITING REF COUNT: 41 THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:672545 CAPLUS
 DOCUMENT NUMBER: 129:275932
 ORIGINAL REFERENCE NO.: 129:56265a, 56268a
 TITLE: Preparation of 3-oxadiazolylquinoxaline derivatives having affinity to benzodiazepine receptor
 INVENTOR(S): Ohno, Kazunori; Odai, Osamu; Furukawa, Kiyoshi; Oka, Makoto
 PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842701	A1	19981001	WO 1998-JP827	19980227 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2002241379	A	20020828	JP 1997-87646	19970321 <--
AU 9861179	A	19981020	AU 1998-61179	19980227 <--
PRIORITY APPLN. INFO.:			JP 1997-87646 WO 1998-JP827	A 19970321 <-- W 19980227 <--
OTHER SOURCE(S): GI	MARPAT	129:275932		




AB Novel 3-oxadiazolylquinoxaline derivs. represented by general formula (I; wherein Het is oxadiazolyl; R1 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, lower alkenyl, lower alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkoxy; R2 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, halogeno, hydroxy, lower alkoxy, cyano, nitro, acyl, optionally substituted benzoyl, amino, lower mono- or dialkylamino, lower alkoxy carbonylmethoxy, lower mono- or dialkylaminocarbonylmethoxy, or optionally substituted benzyloxy; and R3 is hydrogen, lower alkyl, lower cycloalkyl, halogeno, or lower alkoxy), which are useful as a medicine, in particular, which have a selective affinity for benzodiazepine receptors and are useful as a brain activator and a remedy for senile dementia and Alzheimer's disease. Thus, a solution of 1,2-dihydro-2-oxo-3-quinoxalinecarboxylic acid and N,N'-carbonyl diimidazole in DMF was heated with stirring for 3 h at 60°, followed by adding acetamidoxime, and the stirring was continued for another 1.5 h to give 52.6% the title compound (II; R1 = Me; R2 = H). The latter compound and I (R1 = Et, R2 = OMe) inhibited the binding of [³H]diazepam to synaptosome membrane fraction prepared from rat brain with IC₅₀ of 11.5 and 1.41 nM, resp.

IT 213743-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazolylquinoxaline derivs. having affinity to benzodiazepine receptor as brain activators and remedies for senile dementia and Alzheimer's disease)

RN 213743-73-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:210752 CAPLUS

DOCUMENT NUMBER: 128:257445

ORIGINAL REFERENCE NO.: 128:50967a, 50970a

TITLE: Preparation of indolylbenzoquinoxalinones and related compounds as protein kinase C inhibitors.


INVENTOR(S): Bergstrand, Hakan; Karabelas, Kostas; Sjo, Peter
 PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813368	A1	19980402	WO 1997-SE1582	19970919 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1997DE02638	A	20050311	IN 1997-DE2638	19970916 <--
TW 472045	B	20020111	TW 1997-86113549	19970918 <--
ZA 9708469	A	19980325	ZA 1997-8469	19970919 <--
CA 2265854	A1	19980402	CA 1997-2265854	19970919 <--
AU 9744775	A	19980417	AU 1997-44775	19970919 <--
AU 716279	B2	20000224		
EP 929551	A1	19990721	EP 1997-943259	19970919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 334531	A	20000929	NZ 1997-334531	19970919 <--
US 6271231	B1	20010807	US 1997-981266	19971218 <--
US 20010025043	A1	20010927	US 2001-865231	20010525 <--
PRIORITY APPLN. INFO.:			SE 1996-3505	A 19960925 <--
			SE 1997-2747	A 19970718 <--
			WO 1997-SE1582	W 19970919 <--
			US 1997-981266	A3 19971218 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 128:257445

GI




AB Title compds. [I; A, X, Y, Z = C, N; ≥ 2 of A, X, Y, Z = C; may be substituted and/or annulated; excluding 3-(1H-indol-3-yl)-1H-quinoxalin-2-one, 3-(2-methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one], were prepared as protein kinase C inhibitors (no data). Thus, 1,2-phenylenediamine was stirred overnight with [1-[3-(1,3-dioxoisoindol-2-yl)propyl]-1H-indol-3-yl]oxoacetic acid 2,5-dioxopyrrolidin-1-yl ester (preparation given) in THF to give 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium

acetate. The latter was stirred with MeNH₂ in THF/H₂O to give
 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate.
 IT 205377-77-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolylbenzoquinoxalinones and related compds. as protein kinase C inhibitors)
 RN 205377-77-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-6-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 205377-76-0
 CMF C26 H24 N4 O



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1996:527663 CAPLUS
 DOCUMENT NUMBER: 125:167994
 ORIGINAL REFERENCE NO.: 125:31485a, 31488a
 TITLE: Preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders
 INVENTOR(S): Venet, Marc Gaston; Mabire, Dominique Jean-Pierre; Sanz, Gerard Charles
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620200	A1	19960704	WO 1995-EP5173	19951221 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1995CA01685	A	20050304	IN 1995-CA1685	19951220 <--
CA 2207268	A1	19960704	CA 1995-2207268	19951221 <--
AU 9644362	A	19960719	AU 1996-44362	19951221 <--
AU 698199	B2	19981029		
EP 800524	A1	19971015	EP 1995-943237	19951221 <--
EP 800524	B1	20011031		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CN 1171789	A	19980128	CN 1995-197162	19951221 <--
CN 1085668	C	20020529		
JP 10511654	T	19981110	JP 1995-520222	19951221 <--
BR 9510504	A	19990601	BR 1995-10504	19951221 <--
RU 2165419	C2	20010420	RU 1997-112898	19951221 <--
AT 207924	T	20011115	AT 1995-943237	19951221 <--
PT 800524	E	20020429	PT 1995-943237	19951221 <--
ES 2166838	T3	20020501	ES 1995-943237	19951221 <--
PL 182956	B1	20020531	PL 1995-321041	19951221 <--
ZA 9510989	A	19970627	ZA 1995-10989	19951227 <--
IL 116577	A	20000229	IL 1995-116577	19951227 <--
US 5922734	A	19990713	US 1997-860239	19970616 <--
FI 9702794	A	19970627	FI 1997-2794	19970627 <--
NO 9703029	A	19970627	NO 1997-3029	19970627 <--
NO 311220	B1	20011029		
PRIORITY APPLN. INFO.:			EP 1994-203773	A 19941228 <--
			WO 1995-EP5173	W 19951221 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:167994

GI



AB Title compds. [I; R = 3-(F3C)C6H4][II; R1 = H, NH2, alkyl; R2,R3 = H, halo, alkyl; X = O or S; 1 of Z1,Z2 = N and the other = CH] were prepared Thus, (R)-II (R1-R3 = H, X = O, Z1 = N, Z2 = CH) gave complete suppression of estradiol undecylate-induced vaginal keratinization in 50% of ovariectomized rats at 1.25mg/kg orally.

IT 180421-65-2P 180421-66-3P 180421-67-4P
 180421-68-5P 180421-69-6P 180421-70-9P
 180421-71-0P 180421-72-1P 180421-73-2P
 180421-74-3P 180421-75-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders)

RN 180421-65-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 180421-66-3 CAPLUS


CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 180421-67-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-68-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 180421-69-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[fluoro-1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-70-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-71-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 180421-72-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)




RN 180421-73-2 CAPLUS

CN 2(1H)-Quinolinone, 8-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-74-3 CAPLUS

CN 2(1H)-Quinolinone, 5-chloro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-75-4 CAPLUS

CN 2(1H)-Quinolinone, 8-fluoro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT:

3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT:

3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1992:592207 CAPLUS
 DOCUMENT NUMBER: 117:192207
 ORIGINAL REFERENCE NO.: 117:33223a,33226a
 TITLE: Fluorine-19 NMR studies on the mechanism of riboflavin synthase. Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine
 Cushman, Mark; Patel, Hemantkumar H.; Scheuring, Johannes; Bacher, Adelbert
 AUTHOR(S):
 CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA
 SOURCE: Journal of Organic Chemistry (1992), 57(21), 5630-43
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title oxo-(D-ribityl)lumazine I was synthesized by reaction of Me trifluoropyruvate with 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride and utilized as a 19F NMR probe of the light riboflavin synthase of *Bacillus subtilis*. I was found to be an inhibitor of riboflavin synthase with an inhibition constant $K_I = 55 \mu\text{M}$. The enzyme-bound ligand gave rise to several broad 19F NMR signals which were shifted to low field. The bound ligand I could be displaced from the enzyme by the enzyme product, riboflavin (II), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione. Title methyl-(D-ribityl)lumazine III was synthesized by reaction of 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride with 1,1,1-trifluorobutane-2,3-dione. Three mols. of III can be bound relatively tightly per mol of riboflavin synthase, i.e., one ligand mol. per protein subunit. A scheme for the catalytic cycle of riboflavin synthase is proposed.


IT 143309-79-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 143309-79-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

L7 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1992:571381 CAPLUS
 DOCUMENT NUMBER: 117:171381
 ORIGINAL REFERENCE NO.: 117:29633a,29636a

TITLE: Synthesis of pyrido[1',2':1,2]imidazo[4,5-b]quinoxalines
 AUTHOR(S): Tanaka, Kiyoshi; Takahashi, Hideki; Takimoto, Kozo;
 CORPORATE SOURCE: Sugita, Masahiko; Mitsuhashi, Keiryo
 SOURCE: Fac. Eng., Seikei Univ., Musashino, 180, Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): Journal of Heterocyclic Chemistry (1992),
 29(4), 771-7
 CODEN: JHTCAD; ISSN: 0022-152X
 GI



AB Synthesis of title compds. I ($R = H, 8-, 9-\text{Cl}, 8-, 9-\text{Bz}, 8-, 9-\text{NO}_2$; $R1 = H, 1-, 2-, 3-, 4-\text{Me}, 4-\text{PhCH}_2\text{O}$) by the facile cyclizations of 2,3-dichloroquinoxalines II with 2-aminopyridines III and of 2-amino-3-chloroquinoxalines IV ($R \neq H$) with various substituted pyridines is described.
 IT 143702-68-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chlorination of)
 RN 143702-68-5 CAPLUS
 CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

L7 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:612014 CAPLUS
 DOCUMENT NUMBER: 113:212014
 ORIGINAL REFERENCE NO.: 113:35835a, 35838a
 TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines,
 -quinazolines, and -quinoxalines as drugs
 INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston;
 Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard
 Charles
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 106 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 371564	A2	19900606	EP 1989-203014	19891128 <--
EP 371564	A3	19910529		
EP 371564	B1	19950712		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5028606	A	19910702	US 1989-434957	19891113 <--
US 5037829	A	19910806	US 1989-435120	19891113 <--
CA 2002864	A1	19900529	CA 1989-2002864	19891114 <--
CA 2002864	C	19991116		
DK 8905994	A	19900530	DK 1989-5994	19891128 <--
DK 172748	B1	19990628		
NO 8904734	A	19900530	NO 1989-4734	19891128 <--
NO 174509	B	19940207		
NO 174509	C	19940518		
AU 8945646	A	19900607	AU 1989-45646	19891128 <--
AU 620946	B2	19920227		
HU 52498	A2	19900728	HU 1989-6220	19891128 <--
HU 205106	B	19920330		
ZA 8909076	A	19910731	ZA 1989-9076	19891128 <--
SU 1780536	A3	19921207	SU 1989-4742543	19891128 <--
IL 92486	A	19930708	IL 1989-92486	19891128 <--
ES 2088889	T3	19961001	ES 1989-203014	19891128 <--
FI 101964	B	19980930	FI 1989-5687	19891128 <--
FI 101964	B1	19980930		
CN 1042912	A	19900613	CN 1989-108925	19891129 <--
CN 1033752	C	19970108		
JP 02223579	A	19900905	JP 1989-307793	19891129 <--
JP 2916181	B2	19990705		
US 5151421	A	19920929	US 1991-672298	19910320 <--
US 5185346	A	19930209	US 1991-704746	19910523 <--
US 5268380	A	19931207	US 1992-973871	19921110 <--
US 5441954	A	19950815	US 1993-131817	19931005 <--
CN 1106004	A	19950802	CN 1994-117801	19941102 <--
CN 1036002	C	19971001		
CN 1106005	A	19950802	CN 1994-117802	19941102 <--
CN 1036003	C	19971001		
US 5612354	A	19970318	US 1995-409551	19950323 <--
PRIORITY APPLN. INFO.:				
		GB 1988-27820	A	19881129 <--
		GB 1988-27821	A	19881129 <--
		GB 1988-27822	A	19881129 <--
		US 1989-434205	B2	19891113 <--
		US 1989-434957	A3	19891113 <--
		US 1991-704746	A3	19910523 <--
		US 1992-973871	A3	19921110 <--
		US 1993-131817	A3	19931005 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 113:212014

GI For diagram(s), see printed CA Issue.


AB The title compds. [I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl] were prepared as retinoic acid metabolism inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70° with BzCl in DMF containing AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOC12 in THF and the

product II (R1 = Me, R2 = Cl) stirred overnight at 60–70° with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazolo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at ≥10 ng/mL in rats 2 h after oral administration of 40 mg/kg.


IT	120067-41-6P	130344-00-2P	130344-01-3P
	130344-02-4P	130344-03-5P	130346-18-8P
	130346-22-4P	130346-25-7P	130346-26-8P
	130346-27-9P	130346-30-4P	130346-42-8P
	130346-51-9P	130346-66-6P	130346-68-8P
	130346-69-9P	130347-21-6P	130347-22-7P
	130347-23-8P	130347-25-0P	130347-26-1P
	130347-28-3P	130347-30-7P	130347-31-8P
	130347-33-0P	130347-35-2P	130347-37-4P
	130347-39-6P	130347-41-0P	130347-42-1P
	130347-44-3P	130347-45-4P	130347-46-5P
	130347-47-6P	130347-48-7P	130347-62-5P
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as retinoate metabolism and aromatase inhibitor)		
RN	120067-41-6	CAPLUS	
CN	2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)-	(CA INDEX NAME)	




RN	130344-00-2	CAPLUS
CN	2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-	(CA INDEX NAME)




RN	130344-01-3	CAPLUS
CN	2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-	(CA INDEX NAME)




RN	130344-02-4	CAPLUS
CN	2(1H)-Quinolinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-	(CA INDEX NAME)




RN 130344-03-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130346-18-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 130346-22-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)




RN 130346-25-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-26-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-27-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-30-4 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-42-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130346-51-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-phenyl- (CA INDEX NAME)




RN 130346-66-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-68-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 130346-69-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130347-21-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-22-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)




RN 130347-23-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)




RN 130347-25-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, 4-oxide (CA INDEX NAME)




RN 130347-26-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130347-28-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 130347-30-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)




RN 130347-31-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-33-0 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130347-35-2 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-37-4 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)




RN 130347-39-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)




RN 130347-41-0 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-42-1 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)




RN 130347-44-3 CAPLUS

CN 2(1H)-Quinoxalinone, 3-benzoyl-6-(1H-imidazol-1-ylphenylmethyl)-, 4-oxide (CA INDEX NAME)




RN 130347-45-4 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)




RN 130347-46-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)



RN 130347-47-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)




RN 130347-48-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-phenyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA
INDEX NAME)



RN 130347-62-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3,4-dichlorophenyl)-1H-imidazol-1-ylmethyl]-3-

phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)

L7 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:407401 CAPLUS

DOCUMENT NUMBER: 111:7401

ORIGINAL REFERENCE NO.: 111:1422h,1423a

TITLE: Imidazole- or pyridine-containing carbostyrils as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors, their preparation, and pharmaceuticals containing them

INVENTOR(S): Walker, Keith A. M.; Bruno, John J.; Martinez, Gregory R.

PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA

SOURCE: U.S., 20 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792561	A	19881220	US 1986-868845	19860529 <--
US 4921862	A	19900501	US 1988-247134	19880921 <--


PRIORITY APPLN. INFO.:

US 1986-868845 A3 19860529 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 111:7401; MARPAT 111:7401

GI



AB Title compds. I [X = R₁CR₂, cis- or trans-CR₃:CR₄; R₁ = H when R₂ = OH, or R₁ = Ph, phenylalkyl when R₂ = H, OH; Ph is optionally monosubstituted; or R₁R₂ = O, C₁₋₆ alkylidene, (substituted) benzylidene; R₃ = H, C₁₋₆ alkyl; R₄ = H; R₃R₄ = bond; n = 0-3; R = 1-imidazolyl; dotted line = optional covalent bond] are prepared as thromboxane synthetase and cAMP phosphodiesterase inhibitors for treatment of disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels (no data). A mixture of CuI 11.6, (Ph₃P)₂PdCl₂ 86,

N-propargylimidazole (preparation given) 774 mg, and 6-bromo-3,4-dihydrocarbostyryl 1.5 g was stirred in 10mL pyridine and 2 mL triethylamine at 100° for 48 h under N₂. The reaction mixture was then treated with saturated aqueous K₂CO₃, extracted with 10% MeOH in CH₂Cl₂, and


worked up to give 6-[3-(imidazol-1-yl)-1-propyn-1-yl]-3,4-dihydrocarbostyryl. The latter (502 mg) was stirred under H₂ in the presence of 200 mg 10% Pd/C to give 6-[3-(imidazol-1-yl)propyl]-3,4-dihydrocarbostyryl (II). A tablet was formulated containing II 25, cornstarch 20, spray-dried lactose 153, and Mg stearate 2 mg.

IT 120067-41-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cAMP phosphodiesterase and thromboxane synthetase inhibitors)

RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil stnguide
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
```

	SINCE FILE ENTRY	TOTAL SESSION
	92.77	478.03
	-12.75	-12.75

FILE 'STNGUIDE' ENTERED AT 10:30:36 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 26, 2010 (20100326/UP).

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
```

	SINCE FILE ENTRY	TOTAL SESSION
	1.05	479.08
	0.00	-12.75

STN INTERNATIONAL LOGOFF AT 10:39:22 ON 29 MAR 2010